1 week Ago By Defense World Staff
Legal & General Group Plc increased its holdings in Alphatec Holdings, Inc. (NASDAQ:ATEC – Free Report) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).
The institutional investor owned 113,417 shares of the medical technology company’s stock after buying an additional 3,529 shares during the quarter. Legal & General Group Plc owned about 0.08% of Alphatec worth $1,041,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in shares of Alphatec in the fourth quarter worth $29,000. Nisa Investment Advisors LLC grew its position in Alphatec by 973.
3% in the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares in the last quarter. Newton One Investments LLC bought a new stake in shares of Alphatec during the 4th quarter worth about $50,000.
AlphaQuest LLC acquired a new stake in shares of Alphatec in the 4th quarter worth approximately $80,000. Finally, Oppenheimer Asset Management Inc. bought a new position in shares of Alphatec in the fourth quarter valued at approximately $106,000.
66.35% of the stock is currently owned by institutional investors and hedge funds. Insider Activity at AlphatecIn other Alphatec news, CEO Patrick Miles sold 50,000 shares of Alphatec stock in a transaction on Wednesday, January 29th.
The shares were sold at an average price of $12.03, for a total transaction of $601,500.00.
Following the completion of the sale, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at $74,015,104.32. This trade represents a 0.
81 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, COO Scott Lish sold 23,183 shares of the company’s stock in a transaction on Thursday, February 27th.
The stock was sold at an average price of $12.03, for a total transaction of $278,891.49.
Following the completion of the transaction, the chief operating officer now directly owns 844,494 shares in the company, valued at $10,159,262.82. This trade represents a 2.
67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 272,113 shares of company stock valued at $3,121,225.
Corporate insiders own 22.80% of the company’s stock. Analysts Set New Price TargetsATEC has been the subject of a number of research analyst reports.
Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Alphatec in a research report on Thursday, February 27th. Piper Sandler raised their target price on Alphatec from $12.
00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. HC Wainwright reaffirmed a “buy” rating and set a $20.
00 target price on shares of Alphatec in a report on Monday, April 14th. Barclays upped their price target on shares of Alphatec from $20.00 to $21.
00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. Finally, StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th.
Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.
67.Read Our Latest Stock Analysis on ATECAlphatec Price PerformanceATEC opened at $11.51 on Monday.
The firm has a market capitalization of $1.66 billion, a P/E ratio of -8.99 and a beta of 1.
20. The stock has a fifty day moving average of $10.40 and a 200-day moving average of $9.
72. The company has a quick ratio of 1.15, a current ratio of 2.
32 and a debt-to-equity ratio of 30.21. Alphatec Holdings, Inc.
has a 12-month low of $4.88 and a 12-month high of $13.79.
Alphatec (NASDAQ:ATEC – Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
19) by ($0.04). Alphatec had a negative return on equity of 541.
39% and a negative net margin of 31.06%. The business had revenue of $176.
79 million during the quarter, compared to analysts’ expectations of $172.74 million. Equities analysts forecast that Alphatec Holdings, Inc.
will post -1.08 EPS for the current fiscal year. About Alphatec (Free Report)Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally.
It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.See AlsoFive stocks we like better than AlphatecMost Volatile Stocks, What Investors Need to KnowTexas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryStock Sentiment Analysis: How it WorksO’Reilly Automotive: An Anytime Buy for Buy-and-Hold InvestorsWhat Investors Need to Know About Upcoming IPOsChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2.
